false
OasisLMS
Catalog
SCCM Resource Library
Internal Medicine Review 1
Internal Medicine Review 1
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
In this presentation, the speaker discusses the latest research on therapies for COVID-19 critical illness. They focus on three treatments: steroids, anti-interleukin-6 therapies, and Janus kinase (JAK) inhibitors. The speaker explains that in the early stages of COVID-19, antivirals are commonly used to inhibit viral replication. However, as patients progress into moderate and severe illness, inflammation becomes a major driver of organ injury. Steroids, such as dexamethasone, have shown significant benefits in reducing mortality in severe COVID-19 cases. Anti-interleukin-6 therapies, like tocilizumab and sarilumab, have been shown to be effective in reducing mortality and organ support days in critically ill patients. The JAK inhibitor, baricitinib, has also demonstrated potential benefits in reducing mortality. The speaker also highlights other important research areas, such as COVID-19 epidemiology, the impact of air pollution exposure, anticoagulation, and the multisystem inflammatory syndrome.
Asset Subtitle
Research, Quality and Patient Safety, 2022
Asset Caption
This session will highlight the latest research, lessons learned, and changes taking place in critical care internal medicine practice during the past year.
Meta Tag
Content Type
Presentation
Knowledge Area
Research
Knowledge Area
Quality and Patient Safety
Knowledge Level
Foundational
Knowledge Level
Intermediate
Knowledge Level
Advanced
Membership Level
Select
Tag
Outcomes Research
Tag
Evidence Based Medicine
Year
2022
Keywords
COVID-19 critical illness
steroids
anti-interleukin-6 therapies
Janus kinase inhibitors
mortality
organ support days
×
Please select your language
1
English